0001193125-26-204274
SEC filingRevenue accelerated 57.4% to $191.2M from higher AUVELITY and SUNOSI volumes plus SYMBRAVO launch, driving improved cash efficiency despite wider operating losses from commercialization investments.
Revenue reached $191.2 million in Q1 2026, up 57.4% from $121.5 million in the prior year, primarily due to increased unit sales volume for AUVELITY and SUNOSI alongside the commercial launch of SYMBRAVO. This topline momentum reflects successful execution on key products, with increases in line with SUNOSI volume growth in certain ex-U.S. markets and overall sales expansion from the core trio. Management notes that revenue from AUVELITY, SUNOSI, and SYMBRAVO commercial sales is expected to contribute importantly to progress toward profitability, underscoring the strategic focus on these drivers.
Despite revenue growth, operating income was a loss of $63.4 million, 11.2% wider than the $57.0 million loss last year, yielding an operating margin of -33.1%. This reflects the costs of aggressive commercialization, including scaled activities tied to product launches and volume increases. Net income showed a $64.5 million loss, up 8.6% from $59.4 million, with diluted EPS at -$1.26 compared to -$1.22, as expenses rose in tandem with business expansion.
Overall, the quarter demonstrates product momentum translating to revenue and cash improvements, even as losses widen from necessary scaling. The alignment of sales growth with volume and launch dynamics positions the company to leverage its portfolio for sustained progress, consistent with outlook on core revenue contributions.